Table 1.
Clinical demographic of validation sets
| Variable | Validation set 1 (n=331): Cirrhosis with mixed etiology (prospective–retrospective cohort) | Validation set 2 (n=41:123): Cured HCV hepatitis/cirrhosis (nested case-control series)* | Validation set 3 (n=146): Cured HCV hepatitis/cirrhosis after HCC therapies (prospective– retrospective cohort) |
|---|---|---|---|
| Age (y) | 52 (47 – 57) | 72 (62 – 77) : 72 (64 – 76) | 73 (66 – 78) |
| Male sex | 195 (59%) | 23 (56%) : 69 (56%) | 66 (45%) |
| Cirrhosis | 331 (100%) | 30 (73%) : 92 (75%) | 117 (80%) |
| Etiology: HCV/HBV/ARLD/NAFLD/cryptogenic/others | 123/13/60/20/39/76 (37%/4%/18%/6%/12%/23%) | 164/0/0/0/0/0** (100%/0%/0%/0%/0%/0%) | 146/0/0/0/0/0** (100%/0%/0%/0%/0%/0%) |
| Race/ethnicity: white/black/Hispanic/Asian/others | 311/9/8/1/2 (94%/3%/2%/0.3%/1%) | 0/0/0/164/0 (0%/0%/0%/100%/0%) | 0/0/0/146/0 (0%/0%/0%/100%/0%) |
| besity | 140 (42%) | 10 (24%) : 30 (25%) | 20 (14%) |
| Diabetes | 76 (23%) | 5 (12%) : 18 (15%) | 25 (18%) |
| Active hazardous alcohol drink | 34 (11%) | 5 (14%):7 (6%) | 12 (9%) |
| Albumin (g/dL) | 3.4 (2.9 – 3.8) | 3.5 (3.4 – 3.7) : 3.5 (3.3 – 3.8) | 3.6 (3.2 – 3.7) |
| Total bilirubin (mg/dL) | 1.2 (0.8 – 1.9) | 0.9 (0.8 – 1.2) : 0.9 (0.8 – 1.3) | 0.9 (0.7 – 1.1) |
| ALT (IU/L) | 49 (34 – 79) | 20 (17 – 28) : 20 (15 – 28) | 18 (14 – 24) |
| Platelet count (×103/uL) | 95 (67 – 136) | 116 (83 – 152) : 128 (97 – 162) | 115 (91 – 163) |
| AFP (ng/mL) | 3.9 (2.3 – 7.9) | 7 (4–12) : 6 (4–8) | 6 (4 – 10) |
| HCV genotype 1 | n.a. | 36 (88%) : 103 (84%) | 134 (92%) |
| DAA regimen: sofosbuvir-based | - | 11 (27%) : 48 (39%) | 30 (21%) |
| HCC AJCC stage I | - | - | 101 (69%) |
| HCC therapy: resection/ablation/TACE/SRBT | - | - | 43/100/3/2 (29%/68%/2%/1%) |
| Child-Pugh class (A/B/C) | 122/179/25 (37%/55%/8%) | 35/6/0 (85%/15%/0%): 109/14/0 (87%/13%/0%) | 132/14/0 (90%/10%/0%) |
| Follow-up time (y) | 4.5 (1.9 – 11.4) | 1.1 (0.5 – 2.1) : 4.3 (4.0 – 4.6) | 2.9 (0.9–4.1) |
Categorical variables are shown as n (%). Continuous variables are shown as median (IQR).
*
Case:control.
**
All patients achieved sustained virologic response with direct-acting antiviral therapy.
HCV, hepatitis C virus; HBV, hepatitis B virus; ARLD, alcohol-related liver disease; NAFLD, non-alcoholic fatty liver disease; ALT, alanine transaminase; AFP, alpha-fetoprotein; DAA, direct acting antiviral; HCC, hepatocellular carcinoma; AJCC, American Joint Committee of Cancer; TACE, transarterial chemoembolization; SRBT, stereotactic body radiation therapy; IQR, interquartile range; HCC, hepatocellular carcinoma.